GT 3001

Drug Profile

GT 3001

Latest Information Update: 13 Feb 1995

Price : $50

At a glance

  • Originator Gliatech (CEASED)
  • Developer Gliatech (CEASED); Janssen L.P.
  • Class Neuroprotectants; Nootropics
  • Mechanism of Action Amyloid beta-protein precursor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 13 Feb 1995 Discontinued-Preclinical for Alzheimer's disease in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top